Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Initiates PI Study of MDS Treatment FF-10501 in Japan
June 4, 2013
- AZ to Assess Possibility of EGFR Mutation Testing via Blood in Japan-Europe Study
June 3, 2013
- Four Pharmas Launch Filgrastim, Third Biosimilars in Japan
June 3, 2013
- EvaluatePharma Estimates Orphan Drug Market Will Grow to US$127 Billion by 2018
May 31, 2013
- Kyowa Kirin Launches Parkinson’s Disease Treatment Nouriast in Japan
May 31, 2013
- Sawai Aims for All Its New MRs to Pass MR Examination for Fifth Year in a Row
May 31, 2013
- Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
- Eisai Launches Antiepileptic Treatment Inovelon
May 30, 2013
- Nippon Shinyaku Launches Regtect for Supporting Maintenance of Abstinence in Alcohol-Dependent Patients
May 30, 2013
- Ex-Novartis Employee Attended Key Panel Meetings for Diovan Trial
May 29, 2013
- MTPC Files NDA for SGLT-2 Inhibitor Canagliflozin in Japan
May 29, 2013
- Sales of 27 JPMA Member Companies Up 2.6%, First Rise in Two Years Thanks to Overseas Sales Growth
May 28, 2013
- Kyorin Aims for Pentasa Sales Increase in FY2013 with Suppository Formulation: President Yamashita
May 28, 2013
- NPhA Member Companies Will Strive to Reach Price Agreements with Wholesalers by September: Chairman Nakamura
May 28, 2013
- Hisamitsu, Asahi Kasei to Launch Overactive Bladder Treatment Neoxy Tape in June
May 28, 2013
- Astellas Files NDA for Prostate Cancer Treatment Enzalutamide in Japan
May 28, 2013
- “No Indication” of Data Manipulation in Diovan Studies: Novartis
May 27, 2013
- Bayer Launches Anticancer Treatment Stivarga
May 27, 2013
- 2012 Earnings: Foreign Pharmas’ Japan Units Underperform Market Growth, Operating Profit Down 21%
May 27, 2013
- Kyowa Kirin to Launch DPP-4 Inhibitor Onglyza in July Without Concurrent Use Restrictions
May 27, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…